Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Accepted for/Published in: JMIR Research Protocols

Date Submitted: Apr 28, 2022
Date Accepted: May 13, 2022

The final, peer-reviewed published version of this preprint can be found here:

An mHealth App to Promote Adherence to Immunosuppressant Medication and Track Symptoms in Children After Hematopoietic Stem Cell Transplant: Protocol for a Mixed Methods Usability Study

Skeens M, Sezgin E, Stevens J, Landier W, Pai A

An mHealth App to Promote Adherence to Immunosuppressant Medication and Track Symptoms in Children After Hematopoietic Stem Cell Transplant: Protocol for a Mixed Methods Usability Study

JMIR Res Protoc 2022;11(7):e39098

DOI: 10.2196/39098

PMID: 35862184

PMCID: 9353681

A Mobile Health Application to Promote Adherence to Immunosuppressant Medication and Track Symptoms in Children After Hematopoietic Stem Cell Transplant: A Protocol for a Mixed Methods Usability Study

  • Micah Skeens; 
  • Emre Sezgin; 
  • Jack Stevens; 
  • Wendy Landier; 
  • Ahna Pai

ABSTRACT

Background:

In the United States, poor adherence accounts for up to 70% of all medication-related hospital admissions, resulting in $100 billion in healthcare costs annually. In pediatrics, adherence is largely dependent on caregivers. In a high-risk Hematopoietic Stem Cell Transplant (HSCT) population, caregivers are isolated with their child due to infection risk and must manage challenging treatment regimens at home, often with limited time and support. Complex behavioral interventions, typically employed to address adherence, are difficult to deliver and manage in the context of these daily tasks. The most successful adherence interventions, and thus improved clinical outcomes, have included mobile health (mHealth) reminder approaches and a direct measure of adherence.

Objective:

This is a three phase project, with this study protocol describing Phase 2, to determine the usability and feasibility of an mHealth application (app) (BMT4me) designed to promote adherence to immunosuppressant medication and to track symptoms among children who received HSCT.

Methods:

This study uses an iterative, convergent mixed methods design to develop and assess usability and feasibility of an adherence digital health intervention. We will recruit 15 caregivers of pediatric HSCT patients to complete user testing. Qualitative and quantitative data will be integrated to enhance and expand upon study findings.

Results:

We are currently enrolling families and anticipate completion of the study in 4 months.

Conclusions:

This protocol describes a mixed methods usability and feasibility study to develop and implement a smartphone application for caregivers of children receiving HSCT. The app was designed to improve immunosuppressant adherence and to track symptoms in the acute phase post-discharge. Study findings will inform further refinement of the app and the feasibility of a pilot randomized controlled trial examining efficacy on clinical outcomes. Clinical Trial: ClinicalTrials.gov NCT04976933; https://clinicaltrials.gov/ct2/show/NCT04976933


 Citation

Please cite as:

Skeens M, Sezgin E, Stevens J, Landier W, Pai A

An mHealth App to Promote Adherence to Immunosuppressant Medication and Track Symptoms in Children After Hematopoietic Stem Cell Transplant: Protocol for a Mixed Methods Usability Study

JMIR Res Protoc 2022;11(7):e39098

DOI: 10.2196/39098

PMID: 35862184

PMCID: 9353681

Download PDF


Request queued. Please wait while the file is being generated. It may take some time.

© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.